Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Other meaningful insights include: Patient characteristics associated with early uptake Height and weight, enabling calculation of exact BMI, which is critically relevant for this market Clinician-documented attributes relevant to treatment selection, such as other vitals, lifestyle factors, social determinants of health, and other GLP-1 decision drivers HCP prescribing behavior, including identification of early adopters Source of business Differentiation between new-to-therapy patients and switchers Rich insights like thesecaptured early are necessary to understand who is being treated, why specific therapies are chosen, and whether early adoption reflects substitution within the category or expansion of the treated population
Immune cell crosstalk in obesity: a key role for costimulation
In two Phase 3 studies, a fixed-dose combination of cagrilintide and semaglutide (each at 2.4 mg) was associated with weight reductions of 20.4% and 10.4% (placebo subtracted) after once-weekly subcutaneous injection for 68 weeks in overweight/obese individuals without and with type 2 diabetes, respectively (Table 2) [68]
Additionally, these numbers might increase over time, and its possible that three years isnt long enough to determine the actual risk reduction benefit
US$ 22.54
US$ 24.75
US$ 27.63
US$ 24.13
US$ 20.42
US$ 23.94
US$ 26.12
